FDA Explains Trial Design Expectations for Acute Migraine Treatments

Drug Industry Daily
Sponsors of clinical trials for new migraine therapies should focus on enrolling more women of childbearing age early in the drug development process, as more women than men have the condition, according to a new FDA draft guidance.

To View This Article:


Subscribe To Drug Industry Daily